Accuray (NSDQ:ARAY) today released 5-year data from a study of its CyberKnife stereotactic body radiotherapy device for treating prostate cancer, touting a 97% rate of freedom from cancer after treatment at 5-years.
Results from the study were presented at the American Society for Therapeutic Radiology and Oncology’s annual meeting in Boston.
The 21-site, 309-patient trial looked to examine whether dose-escalated SBRT can be administered across multiple institutions without grade 3+ toxicities exceeding 10%. The study followed patients for 5 years and reported toxicity, survival and relapse-free survival outcomes.
At 5 years, overall survival was 95.6%, with a 97.1% rate of relapse-free survival for all patients, as rated by nadir+ definitions. 5 year ASTRO consensus RFS was 92.3% for low risk groups and 91.3% for intermediate-risk groups.
A total of 5 grade 3+ toxicities were reported at 1.6%, well below the 10% rate deemed “excessive”, and no grade 4 or 5 toxicities were reported. Five patients developed urinary intervention which required temporary catheter placement, and 7 patients were diagnosed with bladder cancer between 21 and 50 months, according to the study.
“With appropriate treatment delivery and constraints, dose-escalated prostate SBRT can be safely administered across multiple institutions. Toxicity rates and RFS rates compare favorably to other radiotherapies. SBRT appears to be a suitable option for low- and intermediate-risk prostate cancer,” study authors wrote.
Accuray touted the results, as well as the cost-effectiveness of the system, saying it is “half the cost of IMRT, the most commonly used external beam treatment for prostate cancer.”
The post Accuray touts 5-year CyberKnife data in prostate cancer trial appeared first on MassDevice.
from MassDevice http://ift.tt/2cF9AWM
Cap comentari:
Publica un comentari a l'entrada